Md bio enterprise

The MdBio Foundation, Inc., a private charitable organization that is an affiliate of the Tech Council of Maryland (TCM), today announced that it has received an unrestricted donation of $75,000 from MedImmune, the Gaithersburg, Md.-based global biologics arm of AstraZeneca.

MdBio Foundation will use the donation to support operation of the MdBioLab, its popular mobile bioscience laboratory that travels to schools across Maryland, and development of MdBioSphere™, an innovative interactive digital game that is being designed to enhance high school biology education and awareness.

NewImage

Peter Greenleaf

Peter Greenleaf visited the Department of Business and Economic Development recently to oversee the historic tax credit auction that raised $84 million for the state’s InvestMaryland program. Greenleaf took some time out from his duties as chairman of the Maryland Venture Fund Authority for a quick Q&A about his day job — running MedImmune, one of Maryland’s most successful life sciences companies.

bendis

Chairman Quayle and Ranking Member Edwards, thank you for the opportunity to testify before the House Science, Space and Technology Committee’s Subcommittee on Technology and Innovation on the important topic of “Fostering the U.S. Competitive Edge: Examining the Effect of Federal Policies on Competition, Innovation, and Job Growth.”

My name is Richard Bendis and I am the President and CEO of BioHealth Innovation Inc., (BHI). BHI is a private-public partnership that is predominantly funded by the private sector to foster biohealth innovation-based economic development, which is a unique cluster-based model for regional economic development. This initiative could be used as a model program regardless of industry or cluster strength.

BHI is the first regionally focused innovation intermediary created to connect the university and hospital biohealthresearch strengths of Baltimore with the bioscience industry and federal laboratory strengths of Montgomery County. It has entered into a Partnership Intermediary Agreement with the National Institutes of Health's Office of Technology Transfer and has created the first private-sector funded Entrepreneur in Residence (EIR) program to identify commercializable science in the 27 institutes of NIH. This program will create new project-based companies and high-paying life science jobs. BHI believes this EIR program is applicable to many federal agencies that have technology transfer offices and support SBIR programs.

BHI has designed a potential national pilot, the Health-Regional Innovation Cluster (H-RIC) model, which will incorporate the best innovation-based economic development practices in the United States and integrate them into one region in Central Maryland. BHI is currently seeking federal financial support from several relevant federal agency partners to accelerate the creation and implemention of this innovative biohealth H-RIC model.

Maryland

An initiative aimed at helping Maryland research universities better commercialize technology developments received initial approval by both houses of the General Assembly.

The Maryland Innovation Initiative could provide early funding for tech transfer efforts and encourages collaboration between the University System of Maryland    , Johns Hopkins University    and Morgan State University    . The House of Delegates approved the measure (HB 442) and the Senate approved its companion bill (SB 239).

Johns Hopkins University

Three student groups from Johns Hopkins University are among the 42 teams hailing from some of the world's top universities who will vie for more than $1 million in prizes at the 12th annual Rice Business Plan Competition (RBPC) April 12-14.

The teams for this year's competition were chosen from more than 400 entrants based on their executive summaries to compete in six categories: life sciences; information technology; energy and clean technology; green technology, renewable and recycling; social; and other. The teams will have 15 minutes to present business plans in the competition for the grand prize valued at more than $460,000 and the opportunity to ring the closing bell at NASDAQ OMX this fall. Judges will rank the presentations based on which company they would most likely invest in.

Medical Lights

Crowdsourcing and the world of medicine are already proving strong bedfellows with pharmaceutical giants Eli Lilly and AstraZeneca, who are using open innovation to fund academic research for new treatments and medicines.  However, such ventures are only beneficial as the resources and funding are being made readily available to them, leaving many other research and development projects without the means to get started.

Crowdfunding has already provided a lifeline to charitable, creative and entrepreneurial projects and looks set to offer the same support to medical research, development and provision.

NewImage

That’s not quite a trick question. If you have been preparing a National Institutes of Health (NIH) SBIR/STTR grant submission, you are obviously aware that the deadline is 5 p.m. your local time on Thursday, April 5. However, since January 2011 there have been some important changes in the electronic submission process, so please read the rest of this email closely.

BBC has always advised that you submit your proposals well in advance of the deadline, and we highly encourage you to submit your SBIR/STTR to Grants.gov by April 1. This has always been a good strategy, but now it is essential. The Error Correction Window, which was implemented in December 2005 to facilitate the transition from paper to electronic submission of grant applications, has now been removed. The window had allowed applicants an opportunity after the deadline to correct missing or incorrect aspects of their applications, identified by NIH system-generated errors and warnings displayed to the applicant after submission.

chappell-todd

Chappell will help start-ups based on innovative discoveries 

from NIH and FDA research programs

Todd ChappellROCKVILLE, MARYLAND, March 26, 2012 BioHealth Innovation, Inc. (BHI), a new regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today its selection of Todd Chappell as the first Entrepreneur-in-Residence (EIR) for BHI at the National Institutes of Health (NIH) Office of Technology Transfer (OTT). Mr. Chappell, a venture capital-backed entrepreneurial leader and inventor with more than ten years of experience in molecular biology research, drug development and life sciences business strategy, will help support the development of new start-up companies based upon OTT technology license agreements.

Sequencing the human genome will lead to many diagnostic breakthroughs.

Science and entrepreneurship are both acts of experimentation. Both involve taking risks to reach a positive end, changing course when needed, and attempting the never-been-done. While many start-ups now are focused on creating the next Facebook or some genius e-commerce play, there are also scientists tinkering in labs.

Biotechnology is sometimes forgotten about, but the field leads to real products — new drugs and medical devices that aid human health. Want to cure cancer? These people will be the ones to do it.

NewImage

The recent news that tiny FerroKin BioSciences earned a big buyout deal with Shire ($SHPGY) has helped spotlight the growing popularity of the virtual biotech model. And that has big implications for everyone in the outsourcing industry.

Like other virtuals--such as Stromedix, recently acquired by Biogen Idec ($BIIB)--FerroKin had only a handful of employees working full-time for the company. CROs, CMOs and other outsourcers created a network of support vendors that carried out much of the heavy lifting in drug research. And with some proof of concept data in hand, FerroKin made a tantalizing morsel for an acquirer looking to build up its pipeline without having to acquire a sizable research infrastructure it didn't need.

NewImage

As if we didn’t already know this, yes? Still, a new survey finds that 68 percent of pharma execs agree that Humpty Dumpty has fallen off the wall. To be specific, 44 percent agree that the pharma industry model is broken and 24 percent strongly agree with this statement. Another 22 percent are neutral and 6 percent disagree. We wonder where this 28 percent is working right now…

And over the next two years, 76 percent believe the healthcare system pricing and budget pressures will be the biggest challenge; followed by 70 percent who believe they will have to demonstrate cost effectiveness; 69 percent who cite more restrictive market access; 60 percent who fear generic competition; 53 percent who worry about less access to docs and 50 percent who are concerned about the ability of patients to pay for their meds.

Leggett BHI

A county and state tax credit program leveraged nearly $6 million in investments last year in 10 biotechnology companies in Gaithersburg, Potomac and Rockville, officials said Monday.

Elected officials, including Montgomery County Executive Isiah Leggett (D), Sen. Jennie M. Forehand and Del. Brian J. Feldman joined biotech company executives and representatives of the county’s Department of Economic Development to tout the program at Sequella, Inc. in Rockville.

funding

GlaxoSmithKline and Johnson & Johnson are teaming up with Index Ventures to launch a $200 million fund devoted exclusively to backing early-stage biotechs. And while its primary focus will be in Europe, the venture group intends to invest in biotechs throughout the U.S. as well.

Index takes what it calls an "asset centric" approach to investing, looking for developers with just one or two products--a classic feature of most start-ups. And some heavy hitters from GSK ($GSK) and J&J ($JNJ) will sit on the scientific advisory board of the new fund, giving a few early-stage companies a chance to mix with some top execs from companies they'll be hoping to partner with at some point. From GSK, R&D chief Moncef Slaoui (photo) and Paul-Peter Tak, head of GSK's immunoinflammation therapy area unit, will join Janssen's Paul Stoffels and Bill Hait, global head of R&D. They'll confer with Index Ventures' Francesco De Rubertis, Kevin Johnson, Michele Ollier, Roman Fleck, and Remy Luthringer.